INVEGA SUSTENNA Drug Patent Profile

Which patents cover Invega Sustenna, and when can generic versions of Invega Sustenna launch?

Invega Sustenna is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in twenty-nine countries.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Generic Entry Outlook for Invega Sustenna

Invega Sustenna was eligible for patent challenges on December 19, 2010.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 26, 2031. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (paliperidone palmitate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVEGA SUSTENNA

International Patents:	38
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	11
Patent Applications:	305
Drug Prices:	Drug price information for INVEGA SUSTENNA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVEGA SUSTENNA
What excipients (inactive ingredients) are in INVEGA SUSTENNA?	INVEGA SUSTENNA excipients list
DailyMed Link:	INVEGA SUSTENNA at DailyMed

See drug prices for INVEGA SUSTENNA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INVEGA SUSTENNA

NDA:

022264

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INVEGA SUSTENNA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alliance for Clinical Trials in Oncology	Phase 1
Evolution Research Group	Phase 1
Luye Pharma Group Ltd.	Phase 1

See all INVEGA SUSTENNA clinical trials

Pharmacology for INVEGA SUSTENNA

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for INVEGA SUSTENNA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA SUSTENNA	Extended-release Injectable Suspension	paliperidone palmitate	39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL	022264	1	2017-11-21

US Patents and Regulatory Information for INVEGA SUSTENNA

INVEGA SUSTENNA is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009		RX	Yes	Yes
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-004	Jul 31, 2009		RX	Yes	Yes
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-002	Jul 31, 2009		RX	Yes	Yes

International Patents for INVEGA SUSTENNA

When does loss-of-exclusivity occur for INVEGA SUSTENNA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

New Zealand

Nicaragua

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVEGA SUSTENNA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	122349
Australia	4443689
Australia	614437

Supplementary Protection Certificates for INVEGA SUSTENNA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0368388	91362	Luxembourg		91362, EXPIRES: 20141030
0368388	07C0044	France		PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625
0368388	SPC/GB07/065	United Kingdom		PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021

INVEGA SUSTENNA (paliperidone palmitate) Market Dynamics and Financial Trajectory: Exclusivity Timeline, Generic/Biosimilar Risk, and Revenue Exposure

Last updated: July 24, 2026

Executive summary

• INVEGA SUSTENNA (paliperidone palmitate 1-month injection) is a core Janssen long-acting injectable (LAI) antipsychotic with revenue driven by schizophrenia maintenance use, clinician preference for LAIs, and managed-care contracting.
• Near-to-mid term growth is constrained by patent and regulatory exclusivity ending windows, intensified LAI competition (notably with other paliperidone and risperidone LAIs and newer schizophrenia biologics in the broader mental health spend mix), and payer pressure on injectables.
• The financial trajectory is characterized by steady base revenue with periodic inflection points tied to: (i) label and guideline adoption, (ii) payer tiering and rebate dynamics, (iii) internal product lifecycle within Janssen’s LAI franchise, and (iv) biosimilar and generic threats that can shift share quickly after Paragraph IV or launch carve-outs.

---

What is INVEGA SUSTENNA used for and how does that drive market demand?

INVEGA SUSTENNA is a long-acting injectable antipsychotic indicated for the treatment of schizophrenia. Demand is anchored to maintenance therapy in adults and patients stabilized on paliperidone palmitate who prefer or require non-daily dosing.

How do payer and formulary dynamics affect LAI adoption for schizophrenia?

• LAIs have payer-specific reimbursement and prior authorization structures. Use is commonly steered by:
  • step edits from oral antipsychotics,
  • documentation of adherence problems or clinical instability,
  • preferred LAI tiers and bundle contracting by large health plans.
• Formularies often favor a smaller number of “preferred LAIs,” pressuring non-preferred brands on net price.

What patient segments most influence INVEGA SUSTENNA volume?

• Patients needing adherence support or with prior relapse on oral regimens.
• Clinicians using LAIs to reduce hospitalization risk related to nonadherence.
• Health systems with LAI protocols and nurse-administered injection pathways.

---

What is the competitive landscape for INVEGA SUSTENNA in long-acting injectable schizophrenia treatment?

INVEGA SUSTENNA competes within the LAI schizophrenia market, where switching can be driven by dosing interval convenience, injection volume/site tolerance, and payer preference.

Which brands and LAIs are direct substitutes?

• Paliperidone-based LAIs from Janssen’s portfolio and competitors are the most immediate substitutes because of overlapping clinical utility and clinician familiarity.
• Risperidone LAIs are secondary substitutes for patients and prescribers with legacy workflows.
• In practice, switching is influenced by:
  • interval (1-month vs longer dosing options),
  • titration burden (initiation dosing vs streamlined starts),
  • product handling and stocking requirements,
  • rebates and payer incentives tied to preferred status.

How does dosing interval shape share?

Where a longer-interval LAI exists in the market, payers and providers may prefer it to reduce administration frequency. That creates a built-in headwind for 1-month products over time, even when clinical outcomes are comparable.

---

When does INVEGA SUSTENNA lose exclusivity and what does that mean for future revenue?

Exclusivity timing drives the risk window for generic entry and for erosion through formulary substitution.

How do patent and exclusivity terms translate into revenue risk?

• Revenue risk typically increases in stages:
  1. anticipation and pre-launch contracting (payers tighten terms and demand rebates),
  2. launch readiness by authorized generics or entrants (shifts in inventory and stocking policies),
  3. post-launch share transfer as clinicians switch and payers enforce preferred status.
• LAIs can experience faster share movement than oral drugs because injection-administered care is operationalized through payer contracts and clinic protocols.

What launch scenarios can occur in INVEGA SUSTENNA?

• If patents covering composition, manufacturing, and/or formulation withstand challenges, generic erosion can be delayed.
• If method-of-use or formulation patents are narrower, generic launches can still occur through product design-arounds or partial carve-outs, causing earlier share pressure than investors expect.

---

What patents protect INVEGA SUSTENNA and how strong is the patent estate?

The strength of the patent estate determines how many entry routes remain open for ANDA filers, and how easily challengers can design around.

Patent estate components typically protecting LAI injectables

• Composition of matter for paliperidone palmitate and related chemical forms.
• Formulation and particle engineering claims for controlled release.
• Manufacturing method claims tied to mixing, milling, crystallization conditions, and sterile manufacturing.
• Device or container-and-closure claims (less common but can matter for injection stability and handling).

How does claim scope affect generic design-around feasibility?

• Broad manufacturing and formulation claims make design-around difficult, raising launch delay risk.
• Narrow claims tied to specific process parameters or specific formulation ranges can be attacked more effectively.

---

What generic entry risks exist for INVEGA SUSTENNA and how likely is fast erosion?

For LAIs, the key question is not only whether entry occurs, but how quickly payers can force switching and how easily clinicians can operationalize the switch.

Paragraph IV and settlement dynamics

• If challengers file Paragraph IV certifications against patents listed in the FDA Orange Book, the litigation and any settlement terms can set a “launch calendar” that payers plan around.
• Settlements can include:
  • agreed non-entry dates,
  • market-sharing terms,
  • indemnities,
  • exclusivity protection through agreed covenants not to launch early.

Why LAI switching can be faster than oral substitution

• Administration schedules align with payer incentives and clinic workflows.
• Pharmacy benefits and buy-and-bill contracting can shift preferred status quickly after a launch or settlement trigger.

---

What is the Orange Book status of INVEGA SUSTENNA and what does it imply for filings?

The Orange Book listing determines:

• which patents are enforceable against generic filers,
• whether ANDA applicants can receive approvals only after clearance of specified patents,
• the certification landscape (Paragraph I, II, III, IV).

Orange Book listings influence investor models

• Models depend on the number of listed patents per drug and per dosage strength.
• If many patents expire at different times, there may be stepwise erosion or partial entry depending on which patents are successfully cleared.

---

What FDA regulatory pathway status matters for biosimilar or generic threats?

INVEGA SUSTENNA is a small-molecule drug product, not a biologic. That makes the relevant competitive pathway for generic threat typically ANDA-based (for copies) rather than BLA-based biosimilars.

Why INVEGA SUSTENNA is not a biosimilar story

• Biosimilar frameworks require a reference biologic and molecular comparability.
• Paliperidone palmitate is manufactured as a conventional pharmaceutical drug product.

---

How does INVEGA SUSTENNA manufacturing and supply stability impact financial performance?

LAIs are sensitive to:

• sterile manufacturing capacity,
• validation and process consistency for controlled release,
• supply continuity to avoid missed doses that harm patients and sales.

Supply constraints can shift revenue even absent patent loss

• If supply is limited, sales can be constrained regardless of demand.
• Conversely, stable supply with maintained contract fill rates can support share against competitors.

---

How does INVEGA SUSTENNA compare with other LAI antipsychotics on commercial attributes?

Commercial attributes that drive share include administration burden, patient preference, payer reimbursement, and clinician adoption.

Key comparison dimensions

• Dosing interval and titration schedule.
• Injection site tolerability profile and patient experience.
• Real-world prescribing patterns and managed-care contracting.
• Copay support and distribution model for buy-and-bill.

---

What factors drive net pricing and rebate pressure for INVEGA SUSTENNA?

Net revenue reflects gross sales offset by:

• wholesaler and distributor discounting,
• government rebate obligations (Medicaid, Medicare Part D, and supplemental rebates),
• commercial rebates negotiated based on quarterly performance and share.

How payer bargaining changes after generic entry signals

• Even before launch, challengers and exclusivity end dates can trigger payer demands for additional price concessions.
• LAI portfolio contracts can be re-bid if payers believe switches are imminent.

---

Financial trajectory: how market dynamics map to revenue over time

A practical investor view of INVEGA SUSTENNA revenue typically follows this pattern:

• Phase 1: steady growth or stable base driven by continued LAI adoption, adherence benefits, and contract wins.
• Phase 2: margin compression as rebates rise and payers demand share retention discounts.
• Phase 3: accelerated erosion risk around patent cliff windows and Orange Book clearance steps, with rapid share shift due to LAI operational switching.

Revenue drivers

• Volume growth from LAI penetration into schizophrenia maintenance populations.
• Mix improvements (patients moved to longer duration treatment stability).
• Contracting and formulary placement in large managed care systems.

Revenue headwinds

• Competitive LAI switching due to dosing interval advantages.
• Payer preference programs and downward net price pressure.
• Patent and exclusivity term-driven generic substitution.

---

Key litigation and settlement triggers investors track for LAIs

Even without biosimilar risk, LAI brands are exposed to:

• ANDA filings challenging Orange Book patents,
• court injunction dynamics affecting launch dates,
• settlement covenants shaping payer contracting.

What settlement terms matter commercially

• The date of allowed commercial manufacture and marketing.
• Scope of any carve-outs by dosage form or strength.
• Whether a challenger can market “at risk” versus only after final judgment.

---

Key Takeaways

• INVEGA SUSTENNA’s commercial trajectory is driven by schizophrenia maintenance demand and LAI adoption, but it faces structural pricing and share pressure from competitive LAI substitutes and payer contracting.
• Revenue erosion risk is concentrated in the exclusivity and Orange Book clearance windows, where even small patent victories for generic challengers can shift market share quickly due to LAI switching mechanics.
• The dominant investment question is timing: when enforceable patent coverage clears across relevant dosage strengths and manufacturing/formulation claims, and how quickly payers and clinicians operationalize switching after any generic launch or settlement trigger.

---

FAQs

1) How do LAI buy-and-bill contracts accelerate switching after generic entry for INVEGA SUSTENNA?
Payers can re-tier preferred status and adjust reimbursement quickly, and clinics can switch administration protocols at injection cadence milestones.

2) What patent types matter most for controlled-release LAI products like paliperidone palmitate?
Composition, formulation particle/control-release claims, and manufacturing method claims tied to process parameters are typically the highest-impact patent layers.

3) Does INVEGA SUSTENNA face biosimilar competition?
No. It is a small-molecule drug product, so generic competition via ANDA is the primary pathway rather than biosimilars.

4) What commercial metrics best indicate INVEGA SUSTENNA revenue resilience before a patent cliff?
Managed care share, net price trends (post-rebate), and utilization by high-coverage accounts are the most predictive indicators.

5) How can supply stability change the timing of revenue loss even without patent expiration?
Availability constraints can delay switching by preventing substitution fill, while stable supply can sustain demand through a period when challengers are ramping.

---

References

No sources were cited because no verifiable Orange Book listings, patent numbers, FDA review milestones, or audited financial metrics were provided in the prompt.